Daniel Lamarre, PhD
Dr Lamarre has completed his doctoral studies in biochemistry at the Université de Sherbrooke (Canada) and postdoctoral training in immunology at IRCM (Montreal) and Genentech (San Francisco). He then joined Boehringer Ingelheim R&D Canada, where he contributed to research programs in the areas of HIV and HCV infectious diseases. As the HCV therapeutic head, he established a leading position world-wide with the discovery of BILN 2061 (ciluprevir), the first-in-class antiprotease compound ever tested in human for the treatment of HCV infection. In 2003, he began his academic career at the Université de Montréal as full professor and co-founder of IRIC - one of the first System Biology Research Institute in Canada. Over the last 25 years, Dr. Lamarre has made significant contributions in deciphering molecular aspects of virus-host interactions through system biology approaches focusing his research on the discovery of target-oriented broad-spectrum antiviral and innate immune regulators for the treatment of RNA virus infection. Recently, Dr. Lamarre has co-founded a US-based company to develop innovative long-lasting chimeric antigen receptor (CAR) T-cell therapies to improve survival rates of cancer subjects based on a long-lived pluripotent T stem cell-like memory subset.